Human papillomavirus, cancer and vaccination

Current Opinion in HIV and AIDS

Volumn 6, Issue 4, 2011, Pages 297-302

  Heard, Isabelle ^a,b,c,d  

^a INSTITUT PASTEUR   (France)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

anal cancer; cervical cancer; HIV; human papillomavirus; human papillomavirus vaccines

Indexed keywords

WART VIRUS VACCINE;

ANUS CANCER; ARTICLE; DRUG SAFETY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MOUTH CANCER; NONHUMAN; PAPILLOMAVIRUS INFECTION; POPULATION; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VACCINATION;

FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 79959345078     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328347335d     Document Type: Article

References (38)

1. Ellerbrock TV, Chiasson MA, Bush TJ, et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. J Am Med Assoc 2000; 283:1031-1037. (Pubitemid 30112217)
2. Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA. Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 2009; 101:1120-1130.
3. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States. Ann Intern Med 2008; 148:728-736. (Pubitemid 351717418)
4. Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008; 123:187-194. (Pubitemid 351705208)
5. Massad LS, Seaberg EC, Watts DH, et al. Long-term incidence of cervical cancer in women with human immunodeficiency virus. Cancer 2009; 115:524-530.
6. Franceschi S, Lise M, Clifford GM, et al. Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer 2010; 103:416-422. This study described the changes in pattern of cancer incidence in the Swiss Cohort Study in three different periods: pre-, early- and late-HAART periods, taking into account large shifts in the age distribution of patients.
7. Moodley JR, Hoffman M, Carrara H, et al. HIV and preneoplastic and neoplastic lesions of the cervix in South Africa: a case-control study. BMC Cancer 2006; 6:135.
8. Holmes RS, Hawes SE, Touré P, et al. HIV infection as a risk factor for cervical cancer and cervical intraepithelial neoplasia in Senegal. Cancer Epidemiol Biomarkers Prev 2009; 18:2442-2446.
9. Omar T, Schwartz S, Hanrahan C, et al. Progression and regression of premalignant cervical lesions in HIV-infected women from Soweto: a prospective cohort. AIDS 2011; 25:87-94.
10. Bower M, Mazhar D, Stebbing J. Should cervical cancer be an acquired immunodeficiency syndrome-defining cancer? J Clin Oncol 2006; 24:2417-2419.
11. van der Burg SH, Palefsky JM. Human immunodeficiency virus and human papilloma virus: why HPV-induced lesions do not spontaneously resolve and why therapeutic vaccination can be successful. J Transl Med 2009; 7:108.
12. Nyagol J, Leucci E, Onnis A, et al. The effects of HIV-1 Tat protein on cell cycle during cervical carcinogenesis. Cancer Biol Ther 2006; 5:684-690. (Pubitemid 44024724)
13. Bratcher LF, Sahasrabuddhe VV. The impact of antiretroviral therapy on HPV and cervical intraepithelial neoplasia: current evidence and directions for future research. Infect Agents Cancer 2010; 5:8. This study provides a review of recent studies aimed at evaluating the impact of ART on cervical intraepithelial lesions.
14. Palefsky JM. Anal cancer prevention in HIV-positive men and women. Curr Opin Oncol 2009; 21:433-438.
15. D'Souza G, Cook RL, Ostrow D, et al. Anal cancer screening behaviors and intentions in men who have sex with men. J Gen Intern Med 2008; 23:1452-1457.
16. Piketty C, Selinger-Leneman H, Grabar S, et al. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS 2008; 22:1203-1211.
17. Palefsky J. Human papillomavirus-related disease in people with HIV. Curr Opin HIV AIDS 2009; 4:52-56.
18. Kojic EM, Cu-Uvin S, Conley L, et al. Human papillomavirus infection and cytologic abnormalities of the anus and cervix among HIV-infected women in the study to understand the natural history of HIV/AIDS in the era of effective therapy (The SUN Study). Sex Transm Dis 2011; 38:253-259.
19. Grulich AE, Jin F, Conway EL, et al. Cancers attributable to human papillomavirus infection. Sex Health 2010; 7:244-252.
20. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356:1944-1956. (Pubitemid 46740304)
21. Gillison ML. Oropharyngeal cancer: a potential consequence of concomitant HPV and HIV infection. Curr Opin Oncol 2009; 21:439-444.
22. Bruni L, Diaz M, Castellsagué X, et al. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010; 202:1789-1799.
23. Stanley M. Potential mechanisms for HPV vaccine-induced long-term protection. Gynecol Oncol 2010; 118 (1 Suppl):S2-S7.
24. Giuliano AR, Lu B, Nielson CM, et al. Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J Infect Dis 2008; 198:827-835.
25. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011; 364:401-411.
26. Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011; 11:39-44. This study described the decrease in frequency of genital warts in young Australian women resulting from the high coverage of HPV vaccination, suggesting a protective effect in heterosexual men through herd immunity.
27. Kim HN, Harrington RD, Crane HM, et al. Hepatitis B vaccination in HIV-infected adults: current evidence, recommendations and practical considerations. Int J STD AIDS 2009; 20:595-600.
28. Shrestha S, Sudenga SL, Smith JS, et al. The impact of highly active antiretroviral therapy on prevalence and incidence of cervical human papillomavirus infections in HIV-positive adolescents. BMC Infect Dis 2010; 10:295.
29. Levin MJ, Moscicki A, Song L, et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr 2010; 55:197-204. This study provided the first results of safety and immunogenicity of a HPV-vaccine in HIV-infected infants.
30. Wilkin T, Lee JY, Lensing SY, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 2010; 202:1246-1253. This study provided the first results of safety and immunogenicity of a HPV vaccine in HIV-infected men.
31. De Vuyst H, Lillo F, Broutet N, Smith JS. HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. Eur J Cancer Prev 2008; 17:545-554.
32. Theiler RN, Farr SL, Karon JM, et al. High-risk human papillomavirus reactivation in human immunodeficiency virus-infected women: risk factors for cervical viral shedding. Obstet Gynecol 2010; 115:1150-1158. This study defined reactivation and recurrence of HPV infection and evaluated their implication for cervical cancer screening, prevention and treatment.
33. Luque AE, Hitti J, Mwachari C, et al. Prevalence of human papillomavirus genotypes in HIV-1-infected women in Seattle, USA and Nairobi, Kenya: results from the Women's HIV Interdisciplinary Network (WHIN). Int J Infect Dis 2010; 14:e810-e814.
34. Luchters SMF, Vanden Broeck D, Chersich MF, et al. Association of HIV infection with distribution and viral load of HPV types in Kenya: a survey with 820 female sex workers. BMC Infect Dis 2010; 10:18.
35. McKenzie ND, Kobetz EN, Hnatyszyn J, et al. Women with HIV are more commonly infected with non16 and -18 high-risk HPV types. Gynecol Oncol 2010; 116:572-577. This study described the distribution of HPV genotypes in cervical lesions in HIV-infected women and discussed the potential mechanisms of cervical carcinogenesis in HIV.
36. Cañadas MP, Videla S, Darwich L, et al. Human papillomavirus HPV-16, 18, 52 and 58 integration in cervical cells of HIV-1-infected women. J Clin Virol 2010; 48:198-201.
37. ACOG Practice Bulletin No. 117. Gynecologic care for women with human immunodeficiency virus. Obstet Gynecol 2010; 116:1492-1509.
38. Goldie SJ, Kuntz KM, Weinstein MC, et al. Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men. Am J Med 2000; 108:634-641. (Pubitemid 30336603)